EAM Investors’s Oramed Pharmaceuticals ORMP Stock Holding History

EAM Investors’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-66,392	Closed	-$1.46M	–	348
2021 Q3	$1.46M	Buy	+66,392	New	+$1.13M	0.25%	208

Other funds holding ORMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

EAM Investors's ORMP Position: Q4 2021 in Review

EAM Investors sold out of Oramed Pharmaceuticals (ORMP) in Q4 2021, closing a stake of 66,392 shares — an estimated $1.46M sold.

EAM Investors first reported a position in ORMP in Q3 2021 and held it in 1 quarter. The position peaked at $1.46M in Q3 2021. 116 funds tracked by Wall St. Rank hold ORMP as of Q4 2021.

EAM Investors reported no remaining Oramed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
EAM Investors sold 66,392 Oramed Pharmaceuticals shares in Q4 2021, an estimated $1.46M.
EAM Investors first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 1 quarter.
EAM Investors's Oramed Pharmaceuticals position peaked at $1.46M in Q3 2021.
116 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2021.

Based on EAM Investors's 13F filing for Q4 2021, filed 11 Feb 2022.